Nonalcoholic fatty liver disease

Minerva Medica

Volumn 99, Issue 6, 2008, Pages 583-593

  Hjelkrem, M C ^a   Torres, D M ^b   Harrison, S A ^b  

^a McDonald Army Health Center   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Fatty liver ; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA TOCOPHEROL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; AZACITIDINE; AZASERINE; AZAURIDINE; BETAINE; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; DIDANOSINE; EXENDIN 4; FIALURIDINE; GLUCOCORTICOID; HALOTHANE; HEAVY METAL; HYDRAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG;

ATHEROSCLEROSIS; BARIATRIC SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG INDUCED DISEASE; HISTOPATHOLOGY; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INDUSTRIALIZATION; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOPOROSIS; PREVALENCE; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

CHRONIC DISEASE; FATTY LIVER; HUMANS; PREVALENCE; WEIGHT LOSS;

EID: 59649095267     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Harrison SA. Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004;8:861-79.
2. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003;38:954-61.
3. McCullough A. The epidemiology and risk factors of NASH. In: Farrell G, George J, Hall P, McCullough AJ, editors. Fatty liver disease: NASH and related disorders. Oxford: Blackwell Publishing; 2005. p.23-37.
4. Ludwig J, Viggiano T, McGill D, Oh B. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto un-named disease. Mayo Clin Proc 1980;55:434-8.
5. Angulo P. Nonalcoholic fatty liver disease: N Engl J Med 2002;346: 1221-31.
6. Fracanzani A, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008;121:72-8.
7. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995;127:700-4.
8. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905.
9. Ong JP, younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16.
10. Omagari K, Kadokawa Y, Masuda j, Egawa 1, Sawa T, Hazama H et al. Fatty liver in non-alcoholic non-overweight japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002;17:1098-105.
11. Bellentani S, Saccoccio G, Masutti F, Corce LS, Brandi G, Sasso F et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000;132:112-7.
12. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Tanlguchi H, Fujii K et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8.
13. Nomura H, ashiwagi S, Hayashi J, Kahiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-9.
14. Browning J, Szczepaniak L, Dobins R, Nuremerg P, Horton J, Cohen J et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
15. OngJP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005;15:310-5.
16. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
17. Silverman JF, Pories W,.Caro F. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989;24:275-302.
18. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
19. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
20. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician 2006;73:1961-8.
21. Sanyal AJ. American Gastroenterological Association technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
22. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-9.
23. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007;11:75-104.
24. Bacon BR, Farahvash M, Janney CG, Neushwander-Tetri BA. Nonalcoholic steatohepatiis: an expanded clnical entity. Gastroenterology 1994;107:1103-9.
25. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2468-73.
26. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullogh AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
27. Adams LA, Lymp JF, Sauver JS, Sanderson SO, Lindor KD, Feldstein A et al. The natural history of nonalcoholic fatty liver disease: a population-based study. Gastroenterology 2005;129:113-21.
28. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003;98:2024-47.
29. Fassio E, Alvarez E, Dominquez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6.
30. Hui AY, Wong WS, Chan HLY, Leiw CT, Chan JLY, Chan FKL et al. Histological progression of nonalcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005;21:407-13.
31. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
32. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-67.
33. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11:191-207.
34. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7.
35. Day CP, James OF. Steatohepatitis: a tale of two "hits". Gastroenterology 1998;114:842-5.
36. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91:1125-49.
37. Kim HJ, Lee KE, Kim DJ, Im SK, Ahn CW, Lim SK et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-75.
38. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. J Clin Endocrinol Metab 2004;89:1481-4.
39. Harrison SA, Torres DM. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008;134:1682-98.
40. American Gastroenterology Aassociation guideline: nonalcoholic fatty liver disease. Gastroenterology 2002;123:1702-4.
41. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11:37-54.
42. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, JurleyM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
43. Iijima H, Moriyasu F, Tsuchiaya K, Suzuki S, Yoshida M, Shimizu M et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 2007;37:722-30.
44. Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 207;56:1330-1.
45. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5:1209-13.
46. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007;11:173-89.
47. Kadayifci A, Merriman RB, Bass NM. Medical treatment of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11:119-40.
48. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-9.
49. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother 2003;4:611-23.
50. Fujikawa K, Ohata K, Honda T, Miyazoe S, Ichikawa T, Ishikawa H et al. Nonalcoholic steatohepatitis with improved hepatic fibrosis after weight reduction. Intern Med 2004;43:289-94.
51. O'Leary VB, Marchetti CM, Krishnan Rk, Stetzer BP, Gonzalez F, Kirwan JP. Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol 2006;100:1584-9.
52. Sato F, Tamura Y, Watada H, Kumashiro N, Igarashi Y, Uchino H et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007;92:3326-9.
53. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Coreses C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2002;98:926-30.
54. Harrison SA, Fincke C, Helinsi D. Orlistat treatment in obese, non-alcoholic patients: a pilot study. Hepatology 2002;36:406A.
55. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels inobese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-92.
56. Scheen AJ. Cannabinoid-1 receptor antagonists n type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21:535-53.
57. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C Carlsson B et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93.
58. Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L Feirt N et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006;130:1564-72.
59. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006;130:1617-24.
60. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58.
61. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in mobidly obese subjects. J Hepatol 1991;12:224-9.
62. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990;47:208-14.
63. Lin HZ, Yang S, Chuckaree C, Kuhagda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
64. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Devici S, Tuzunn A et al. Metformin in the treatment of patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-544.
65. Nair S, Diehl AM, Wiseman M, Fair GH, Perrilo RP. Metformin in the treatment of non-alcholoic steatohepatitis a pilot open label trial. Aliment Pharmacol Ther 2004;20:23-28.
66. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
67. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
68. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Haries J et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
69. Aithal GP, Thomas JA, Kaye P, Lawson A, Ryder SD, Austin AS et al. A randomized, double blind, placebo controlled trial of one year of pioglitazone in non-diabetic subjects with nonalcoholic steatohepatitis. Hepatology 2007;46(Suppl 1):295A.
70. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 2007;41:2014-18.
71. Nissen SE, Wolski k. Effect of rosiglitazone on the reisk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
72. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90.
73. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK et al. A pilot study of Vitamin E versus Vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-15.
74. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-9.
75. Miller ER III, Pastor-Varriuso R, Dalai D, Riemersma RA, Appel LJ, Gualler E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
76. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucoronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000;50:722-7.
77. Abdelmalek MF, AnguloP, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-17.
78. Shapiro H, Bruck R. Omega-3 may indirectly reduce hepatocyte triglycerides through modulation of hyperinsulinemia, cytokines and adipocytokines. Am J Cardiol 2007;99:146.
79. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006;169:846-60.
80. Capanni M, Calella F, Centenaro G, Biagini M, Svegliati-Baroni G, Melani S et al. Prolonged N-3 PUFA dietary supplementation improves fatty liver in patients with NAFLD. Aliment Pharmacol Ther 2006;23:1143-51.
81. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
82. Ding X, Saxena NK, Lin S, Gupta NA, Gupta N, Anania FA. Exendin-4, a glucagon-like protein 1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-81.
83. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-7.
84. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96.
85. Pershadsingh H.A. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int J Biochem Cell Biol 2006;38:766-81.
86. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-5.
87. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473-80.
88. Targher G, Berolini L, Padovani R, Rodella S, Zoppini G, Zenari L et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325-30.
89. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92.
90. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004;71:58-62.
91. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C et al. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Stroke 2002;33:2337-41.
92. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31:384.
93. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193-6.